# Hashimoto Thyroiditis

Diagnose Hashimoto thyroiditis by integrating TSH/free T4 status with TPO or thyroglobulin antibodies and, when needed, ultrasound; treat thyroid hormone deficiency rather than antibody positivity, optimize levothyroxine administration before escalating dose, and intensify surveillance during pregnancy and postpartum.

**Clinical question:** How should clinicians confirm Hashimoto thyroiditis, decide when to replace thyroid hormone, and monitor patients over time?

Updated: 2026-09-16T00:20:14.082468+00:00

## What matters in practice
- Use TSH and free T4 to determine the treatment state; TPOAb and TgAb support autoimmune etiology but do not by themselves require thyroid hormone treatment. [17][10]
- Overt primary hypothyroidism—elevated TSH with low free or total T4—requires levothyroxine replacement. [17]
- For mild subclinical hypothyroidism, immediate levothyroxine is not universal; monitor TSH once or twice yearly when treatment is deferred. [17]
- Before increasing levothyroxine for an elevated TSH, verify fasting administration and separation from iron, calcium, aluminum hydroxide, and proton-pump inhibitors. [10]
- Pregnancy and the 2- to 6-month postpartum interval can substantially change autoimmune thyroid activity and thyroid hormone requirements. [15]

## Confirm autoimmune thyroiditis and define the functional state

The immediate decision is not antibody status; it is whether thyroid hormone deficiency is present.

Order serum TSH and free T4 when Hashimoto thyroiditis is suspected clinically or from thyroid enlargement. Elevated TSH with low free T4 establishes overt hypothyroidism and warrants replacement. Elevated TSH with normal free T4 is subclinical hypothyroidism; normal TSH and free T4 indicate euthyroid autoimmune thyroiditis if antibodies or imaging support the diagnosis. [17][10]

Measure TPO antibodies as the principal serologic marker and add Tg antibodies when the diagnostic picture remains uncertain. TPO antibodies are present in approximately 80% to 90% of patients with autoimmune thyroid disease, while a clinically or ultrasonographically diagnosed antibody-negative phenotype occurs in about 5% of patients. A negative antibody result therefore lowers, but does not eliminate, the probability of Hashimoto thyroiditis. [2][16]

Use thyroid ultrasound selectively when the gland is enlarged, palpably irregular, or antibody testing is negative despite persistent clinical suspicion. Compatible findings include diffuse hypoechogenicity and heterogeneous parenchyma; ultrasound can show inflammatory change even while thyroid hormone tests remain normal. Do not use an ultrasound pattern alone to determine whether levothyroxine is indicated; treatment remains driven by thyroid function. [12][17][15]
- Overt hypothyroidism: elevated TSH plus low free or total T4; initiate levothyroxine. [17]
- Subclinical hypothyroidism: elevated TSH with normal thyroid hormone level; decide between observation and treatment based on clinical context rather than antibody positivity alone. [17]
- Euthyroid autoimmune thyroiditis: normal TSH and free T4 with TPOAb/TgAb positivity or compatible ultrasound; do not prescribe thyroid hormone solely for antibodies. [17]

*Interpretation of initial testing in suspected Hashimoto thyroiditis. [17][12][16]*

| Pattern | Most likely interpretation | Next action |
| --- | --- | --- |
| Elevated TSH with low free or total T4 | Overt hypothyroidism due to autoimmune thyroiditis when TPOAb/TgAb or ultrasound supports etiology. [17][12] | Start titrated oral levothyroxine and follow thyroid function during dose adjustment. [10][5] |
| Elevated TSH with normal thyroid hormone level | Subclinical hypothyroidism; antibody-positive disease may carry greater likelihood of progression than antibody-negative disease. [17][16] | Consider clinical context; if deferring treatment, check TSH once or twice yearly. [17] |
| Normal TSH and free T4 with positive TPOAb or TgAb | Euthyroid autoimmune thyroiditis. [17][19] | No thyroid hormone replacement; monitor thyroid function longitudinally. [17] |
| Negative antibodies with heterogeneous, hypoechoic thyroid on ultrasound | Possible seronegative Hashimoto thyroiditis. [16][12] | Base treatment on TSH and free T4, not on ultrasound alone. [17] |

## Do not misclassify transient thyrotoxicosis or nonautoimmune hypothyroidism

An abnormal thyroid panel should be interpreted in its temporal and etiologic context.

A transient hyperthyroid phase can occur in Hashimoto thyroiditis from follicular destruction and release of stored hormone. In a patient with suppressed TSH and biochemical thyrotoxicosis, do not assume Graves disease solely because thyroid autoimmunity is present; thyroid autoantibodies may be associated with both Graves disease and Hashimoto thyroiditis. Reassess the evolving thyroid function pattern and clinical phenotype before committing to a hyperthyroidism-specific treatment pathway. [10][1][19]

When hypothyroidism is present, document competing causes before assigning all disease to Hashimoto thyroiditis. Prior neck or thyroid surgery, thyroid irradiation, radioiodine treatment for Graves disease, and medications affecting thyroid function are alternative etiologies; primary hypothyroidism is far more common than secondary disease. This distinction matters because positive thyroid antibodies can coexist with another reason for reduced thyroid reserve. [24]

Escalate beyond routine autoimmune testing when structural findings are discordant with diffuse thyroiditis—for example, a rapidly enlarging gland or a concerning focal process. Hashimoto thyroiditis can produce multiple ill-defined sonographic nodules, whereas rapid enlargement may also occur with anaplastic thyroid cancer or infiltrative disease; a focal or rapidly progressive structural concern requires directed thyroid evaluation rather than serial antibody measurement. [15][22]
- Obtain history of thyroidectomy, neck irradiation, radioiodine exposure, and thyroid-active medications when TSH is elevated. [24]
- Interpret positive TPOAb/TgAb as evidence of thyroid autoimmunity, not proof that every abnormal thyroid test reflects Hashimoto thyroiditis. [19][24]
- A rapidly enlarging thyroid or suspicious focal structural change should trigger focused structural assessment rather than routine longitudinal observation. [22][15]

*Actionable etiologic distinctions in patients with suspected Hashimoto thyroiditis. [10][19][22][24]*

| Clinical pattern | Discriminator | Management consequence |
| --- | --- | --- |
| Thyrotoxicosis in a patient with autoimmune markers | Hashimoto thyroiditis can cause a transient destructive hyperthyroid phase; autoantibodies can also occur in Graves disease. [10][19] | Avoid assigning a permanent hyperthyroid diagnosis from antibody status alone; follow the biochemical and clinical trajectory. [10] |
| Hypothyroidism after radioiodine, surgery, or neck irradiation | Clear iatrogenic exposure history. [24] | Treat hormone deficiency but document iatrogenic thyroid loss as the principal or contributing cause. [24] |
| Rapid gland enlargement or atypical structural progression | Rapid enlargement may reflect processes beyond autoimmune thyroiditis, including anaplastic thyroid cancer or infiltrative disease. [22] | Pursue focused thyroid structural evaluation rather than attributing change to stable Hashimoto thyroiditis. [22] |

## Use levothyroxine for hypothyroidism, not for antibody positivity

Replacement corrects hormone deficiency but does not reliably halt the autoimmune process.

Initiate oral levothyroxine for clinical hypothyroidism from Hashimoto thyroiditis. Available dosing references describe a typical adult maintenance requirement of about 1.7 mcg/kg/day, commonly 100 to 150 mcg/day, but starting dose should be individualized to age and cardiac risk. In older adults or patients considered dose-sensitive, begin 25 to 50 mcg daily; in elderly patients with coronary artery disease, 12.5 mcg daily is advised because more rapid replacement can precipitate angina. [5]

Adjust the dose in 25-mcg increments no more often than every 6 to 8 weeks, using serum TSH and clinical response. One source describes titration every 6 weeks until thyroid function tests normalize, followed by thyroid testing every 6 months or sooner when symptoms recur. Keep the patient on a consistent levothyroxine formulation when feasible because formulation changes may introduce clinically meaningful dose variability. [5]

For patients with high thyroid antibody levels but normal TSH and free T4, do not use levothyroxine merely to treat seropositivity. For mild subclinical hypothyroidism, medication may be deferred, with TSH checked once or twice per year to identify progression to clinical hypothyroidism. This approach separates management of autoimmune risk from treatment of biochemical hormone deficiency. [17]

Address apparent under-replacement before reflexively escalating dose. Levothyroxine is best taken early in the morning on an empty stomach; iron, calcium, aluminum hydroxide, and proton-pump inhibitors can impair absorption. Review timing and interacting products at each unexplained TSH elevation, then repeat thyroid function testing after the corrected administration routine and adequate titration interval. [10]
- Typical adult maintenance estimate: approximately 1.7 mcg/kg/day; commonly 100 to 150 mcg/day. [5]
- Older or dose-sensitive patient: start 25 to 50 mcg orally daily. [5]
- Elderly patient with coronary artery disease: start 12.5 mcg orally daily. [5]
- Dose adjustment: increase by 25 mcg at 6- to 8-week intervals according to TSH and clinical response. [5]
- Administration: take fasting; separate from iron, calcium, aluminum hydroxide, and proton-pump inhibitors. [10]

### When symptoms persist despite euthyroid testing

Confirm TSH and free T4, adherence, formulation consistency, fasting administration, and interacting agents before attributing persistent symptoms to refractory Hashimoto thyroiditis. Levothyroxine corrects hypothyroidism but does not block the autoimmune process, and persistent symptoms in a biochemically euthyroid patient should prompt evaluation for nonthyroid contributors rather than automatic dose escalation. [9][10]
- Do not use symptoms alone to justify increasing levothyroxine when thyroid function tests have normalized. [5][9]
- Review iron, calcium, aluminum hydroxide, and proton-pump inhibitor exposure before labeling levothyroxine failure. [10]

*Levothyroxine dosing and follow-up points supported for Hashimoto-related hypothyroidism. [5][10][17]*

| Clinical situation | Dose or action | Monitoring or caution |
| --- | --- | --- |
| Typical adult replacement | Average maintenance requirement about 1.7 mcg/kg/day, often 100 to 150 mcg/day. [5] | Titrate to thyroid function test normalization and symptom response. [5] |
| Older or dose-sensitive patient | Start 25 to 50 mcg orally daily. [5] | Adjust by 25 mcg every 6 to 8 weeks. [5] |
| Elderly patient with coronary artery disease | Start 12.5 mcg orally daily. [5] | Avoid rapid escalation because higher initial doses may precipitate angina. [5] |
| Elevated TSH despite prescribed therapy | Verify fasting dosing and separation from iron, calcium, aluminum hydroxide, and proton-pump inhibitors. [10] | Correct administration barriers before increasing dose; reassess after an adequate titration interval. [10][5] |
| Positive antibodies with normal TSH and free T4 | Do not prescribe thyroid hormone for seropositivity alone. [17] | Monitor thyroid function longitudinally. [17] |

## Plan earlier monitoring in pregnancy and the postpartum period

Pregnancy alters thyroid autoimmunity and can change replacement requirements.

In patients with established Hashimoto-related hypothyroidism who become pregnant, continue levothyroxine and monitor TSH serially because pregnancy changes thyroid physiology and dose requirements. Pregnancy-specific management requires special consideration because maternal thyroid dysfunction can adversely affect pregnancy; historical guidance cited in current reviews supports dedicated pregnancy and postpartum thyroid management. [15][13]

TPO antibody positivity has prognostic relevance even when thyroid function is not overtly abnormal: it is associated with a 2- to 4-fold increased risk of recurrent miscarriage and preterm birth. This association should prompt deliberate thyroid-function surveillance and obstetric coordination rather than empiric thyroid hormone treatment solely on the basis of antibodies when the patient remains euthyroid. [13][17]

Recheck thyroid function after delivery because antibody levels generally decline during pregnancy, then rise postpartum; goiter and hypothyroidism may emerge or recur 2 to 6 months after delivery. Patients whose levothyroxine requirement changed during gestation need a documented postpartum testing plan rather than waiting for symptoms alone. [15]
- Continue levothyroxine in pregnant patients with established hypothyroidism and use serial TSH monitoring for dose adjustment. [15][21]
- Recognize TPOAb positivity as associated with a 2- to 4-fold increased risk of recurrent miscarriage and preterm birth. [13]
- Schedule postpartum thyroid reassessment because autoimmune activity and hypothyroidism can recur 2 to 6 months after delivery. [15]

*Pregnancy-related decision points in Hashimoto thyroiditis. [13][15][17]*

| Time point | Risk or interpretation | Clinical action |
| --- | --- | --- |
| Preconception or early pregnancy | TPOAb positivity is associated with a 2- to 4-fold increased risk of recurrent miscarriage and preterm birth. [13] | Assess thyroid function and coordinate pregnancy-specific management. [13][15] |
| During pregnancy with treated hypothyroidism | Thyroid physiology and levothyroxine requirements may change. [15][21] | Continue levothyroxine and monitor TSH serially for dose adjustment. [15][21] |
| Two to six months postpartum | Antibody levels may rise after delivery, with sudden goiter and hypothyroidism. [15] | Repeat thyroid function testing even if symptoms are nonspecific. [15] |

## Monitor thyroid function and use associated autoimmune disease as a clinical trigger

Hashimoto thyroiditis evolves from euthyroidism or subclinical disease to persistent hypothyroidism in some patients.

Follow untreated euthyroid or mildly subclinical disease with periodic TSH rather than serial antibody titers. For a patient with elevated antibodies but normal thyroid function, thyroid hormone is not required; for mild subclinical hypothyroidism when treatment is deferred, check TSH once or twice per year. The relevant progression endpoint is clinical hypothyroidism, defined by elevated TSH with low thyroid hormone level. [17][12]

Use the clinical history to identify clustering of autoimmune disease. Hashimoto thyroiditis is frequently associated with vitiligo, Addison disease, and type 1 diabetes, including autoimmune polyglandular syndrome type 2. Target evaluation toward symptoms or established disease patterns rather than using the Hashimoto diagnosis alone as a mandate for indiscriminate testing. [12][24]

A persistent or enlarging goiter deserves examination at follow-up even when thyroid function is stable. Hashimoto thyroiditis may produce diffuse enlargement and heterogeneous or very low-echogenicity ultrasound changes, but new focal or rapidly progressive structural findings should redirect evaluation toward thyroid pathology beyond routine autoimmune monitoring. [15][22]
- Euthyroid antibody-positive disease: no levothyroxine; monitor thyroid function. [17]
- Mild subclinical hypothyroidism managed without medication: measure TSH once or twice yearly. [17]
- Screen clinically for associated autoimmune disease when symptoms suggest vitiligo, adrenal insufficiency, or type 1 diabetes. [12][24]
- Reassess a changing goiter structurally; do not use stable antibody positivity as reassurance against a new focal process. [15][22]

*Longitudinal follow-up priorities in Hashimoto thyroiditis. [12][15][17][22]*

| Follow-up finding | Interpretation | Next step |
| --- | --- | --- |
| Normal TSH and free T4 with antibody positivity | Autoimmune thyroiditis without current hormone deficiency. [17] | No replacement therapy; continue thyroid-function monitoring. [17] |
| Mild subclinical hypothyroidism without immediate treatment | Possible progression to clinical hypothyroidism. [17][12] | Check TSH once or twice yearly. [17] |
| Symptoms suggesting vitiligo, Addison disease, or type 1 diabetes | Autoimmune clustering is recognized in Hashimoto thyroiditis. [12] | Direct testing to the suspected associated autoimmune disorder. [12][24] |
| New focal finding or rapid gland enlargement | Possible pathology beyond routine chronic thyroiditis. [22][15] | Undertake focused structural thyroid evaluation. [22] |

## References
1. Autoimmune Thyroiditis - an overview | ScienceDirect Topics — sciencedirect.com — https://sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/autoimmune-thyroiditis
2. Autoimmune Thyroiditis - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/autoimmune-thyroiditis
3. Hypothyroidism and chronic autoimmune thyroiditis in the pregnant state: maternal aspects - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1521690X0400017X
4. What antibody studies are helpful in the... : Evidence-Based Practice — journals.lww.com — https://journals.lww.com/ebp/fulltext/2012/01000/what_antibody_studies_are_helpful_in_the_diagnosis.7.aspx
5. Levothyroxine Sodium - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/neuroscience/levothyroxine-sodium
6. Rook's Textbook of Dermatology — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdf/10.1002/9780470750520.index
7. Abstract - 2024 - JPGN Reports — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/jpr3.12148
8. Flash talks (FT) - 2024 - Allergy - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/all.16299
9. Hashimoto’s thyroiditis: from pathogenesis to clinical management — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12907336
10. Hashimoto Thyroiditis - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK459262
11. Current Practices in Hashimoto’s Thyroiditis: Differences in Attitudes Between Pediatric and Adult Endocrinologists in Türkiye: A National Survey - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12372645
12. [Autoimmune thyroiditis (Hashimoto's thyroiditis): current diagnostics and therapy] - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/20676951
13. Hashimoto thyroiditis: an evidence-based guide to etiology, diagnosis and treatment — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9478900
14. Persistent symptoms in euthyroid Hashimoto’s thyroiditis: current hypotheses and emerging management strategies — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12313505
15. Hashimoto’s Thyroiditis - Endotext - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK285557
16. Vol 7 Issue 9 p.10-11 |  American Thyroid Association — www.thyroid.org — https://www.thyroid.org/patient-thyroid-information/ct-for-patients/vol-7-issue-9/vol-7-issue-9-p-10-11
17. [PDF] Hashimoto's Thyroiditis — www.thyroid.org — https://www.thyroid.org/wp-content/uploads/patients/brochures/Hashimotos_Thyroiditis.pdf
18. Vol 15 Issue 8 p.9-10 |  American Thyroid Association — www.thyroid.org — https://www.thyroid.org/patient-thyroid-information/ct-for-patients/august-2022/vol-15-issue-8-p-9-10
19. Vol 4 Issue 10 p.11-12 | American Thyroid Association — www.thyroid.org — https://www.thyroid.org/patient-thyroid-information/ct-for-patients/vol-4-issue-10/vol-4-issue-10-p-11-12
20. Antithyroid peroxidase autoantibodies in thyroid diseases - PubMed — www.ccjm.org — https://www.ccjm.org/lookup/external-ref?access_num=2168432&link_type=MED&atom=%2Fccjom%2F92%2F4%2F221.atom
21. Thyroid Peroxidase Antibody - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/neuroscience/thyroid-peroxidase-antibody
22. Euthyroidism - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/euthyroidism
23. Celiac disease detection in hypothyroid patients requiring elevated thyroid supplementation: A prospective cohort study - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0953620515002964
24. Hypothyroidism - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/hypothyroidism

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.